Stock Alert: CNS Pharma Up On Brain Cancer Trial Update

Shares of CNS Pharmaceuticals Inc. (CNSP) are up 16 percent in pre-market trading on Tuesday, following news that one patient from a phase I clinical trial of the Company's lead asset Berubicin in glioblastoma multiforme, an aggressive type of brain cancer, continues to remain cancer-free.

The phase I trial was conducted in 2002 by Reata Pharmaceuticals Inc (RETA), to which Berubicin was initially licensed.

Previously Reported Trial Results:

In the phase I trial, which involved 25 evaluable patients, 11 patients experienced a statistically significant improvement in progression-free survival - and that reflects a PFS rate of 44%.

One patient experienced a durable complete response, which is defined by the National Cancer Institute as the disappearance of all signs of cancer in response to treatment.

What Next?

CNS Pharma expects to initiate its phase II clinical trial of Berubicin in glioblastoma multiforme in the second half of this year with its partner, WPD Pharmaceuticals Inc., subject to the FDA granting the go-ahead.

In addition, WPD Pharma is expected to commence the first-ever phase I trial of Berubicin in children later this year.

Last November, CNS Pharma granted WPD Pharmaceuticals patent rights to research and develop, and manufacture or sell Berubicin in a limited territory comprised mainly of Eastern Europe and Central Asia.

CNSP has traded in a range of $3.40 to $5.69 in the last 1 year. In pre-market trading Tuesday, the stock is up 16.62% at $4.49.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT